Compile Data Set for Download or QSAR
maximum 50k data
Found 2921 with Last Name = 'anand' and Initial = 'k'
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/mole IC50:  5.60nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM50027366(Ketazocine | US10081602, Example Ketazocine | US10...)
Affinity DataKi:  1.30nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  2.86nM ΔG°:  -48.8kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  2.86nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  2.86nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  5nM ΔG°:  -47.4kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475934(Preparation of (2S,6R,11R)-8-((4-(2,5,8,11,14-pent...)
Affinity DataKi:  5nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  5nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  44nM ΔG°:  -42.0kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  44.3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168148(US10081602, Example 20 | US10865186, Compound 20 |...)
Affinity DataKi:  44.3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  58nM ΔG°:  -41.3kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475934(Preparation of (2S,6R,11R)-8-((4-(2,5,8,11,14-pent...)
Affinity DataKi:  58.5nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168147(US10081602, Example 12 | US9688638, 12)
Affinity DataKi:  58.5nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataKi:  203nM ΔG°:  -38.2kJ/mole IC50:  879nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285849((2S,6R,11R)-3-(Cyclopropylmethyl)-8-{2-[2-(2-metho...)
Affinity DataKi:  203nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataKi:  203nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  494nM ΔG°:  -36.0kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  494nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  494nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataKi:  549nM ΔG°:  -35.7kJ/mole IC50:  2.38E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285847((2S,6R,11R)-3-(Cyclopropylmethyl)-6,11-dimethyl-8-...)
Affinity DataKi:  549nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475929(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-6...)
Affinity DataKi:  549nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataKi:  619nM ΔG°:  -35.4kJ/mole IC50:  2.68E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475928(Preparation of (2S,6R,11R)-3-(cyclopropylmethyl)-8...)
Affinity DataKi:  619nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285816((2S, 6R, 11R)-3-(Cyclopropylmethyl)-8-({2-[2-(2-me...)
Affinity DataKi:  619nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM166783(US9688638, 1 | US9688638, 2 | US9688638, 3)
Affinity DataKi:  769nM ΔG°:  -34.9kJ/mole IC50:  3.33E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285848((2S,6R,11R)-3-(Cyclopropylmethyl)-8-(2,5,8,11,14,1...)
Affinity DataKi:  769nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475930(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-8...)
Affinity DataKi:  769nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  955nM ΔG°:  -34.4kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  955nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475939(Preparation of (1R,2S,6R,11R)-1-(2,5,8,11,14-penta...)
Affinity DataKi:  955nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  1.06E+3nM ΔG°:  -34.1kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  1.06E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  1.06E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataKi:  1.40E+3nM ΔG°:  -33.4kJ/mole IC50:  6.08E+3nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475933(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-8...)
Affinity DataKi:  1.40E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285851((2S,6R,11R)-3-(Cyclopropylmethyl)-8-(2,5,8,11,14,1...)
Affinity DataKi:  1.40E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  1.81E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  1.81E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168150(US10081602, Example 24 | US10865186, Compound 24 |...)
Affinity DataKi:  1.81E+3nM ΔG°:  -32.8kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168144(US10865186, Compound 4 | US9688638, 4 | US9688638,...)
Affinity DataKi:  2.96E+3nM ΔG°:  -31.6kJ/mole IC50:  1.28E+4nMpH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM285850((2S,6R,11R)-3-(Cyclopropylmethyl)-6,11-dimethyl-8-...)
Affinity DataKi:  2.96E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475932(Preparation of (2S,6R,11R)-3-(Cyclopropylmethyl)-6...)
Affinity DataKi:  2.96E+3nMAssay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  3.92E+3nM ΔG°:  -30.9kJ/molepH: 7.5 T: 2°CAssay Description:Competition binding experiments were conducted by incubating membrane protein to equilibrium in triplicate in the presence of a fixed concentration o...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM475939(Preparation of (1R,2S,6R,11R)-1-(2,5,8,11,14-penta...)
Affinity DataKi:  3.92E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168151(US10081602, Example 25 | US9688638, 25)
Affinity DataKi:  3.92E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  7.96E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
Nektar Therapeutics

US Patent
LigandPNGBDBM168149(US10081602, Example 23 | US10865186, Compound 23 |...)
Affinity DataKi:  7.96E+3nMpH: 7.5Assay Description:The binding affinities of certain compounds of the present invention were evaluated using radioligand binding assays in membranes prepared from CHO-K...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 2921 total ) | Next | Last >>
Jump to: